Valenstein Marcia, Ganoczy Dara, McCarthy John F, Myra Kim Hyungjin, Lee Todd A, Blow Frederic C
Department of Veterans Affairs, Ann Arbor Center of Excellence (COE), Serious Mental Illness Treatment Research and Evaluation Center (SMITREC), Ann Arbor, MI 48113-0170, USA.
J Clin Psychiatry. 2006 Oct;67(10):1542-50. doi: 10.4088/jcp.v67n1008.
Approximately 40% of patients with schizophrenia are poorly adherent to their antipsychotics at any given time. However, little is known about patients' adherence over time, although this has important services implications. We examined antipsychotic adherence over 4 years at the aggregate and the individual level among a large cohort of patients.
We identified 34,128 Veterans Affairs patients who received a schizophrenia diagnosis and an antipsychotic fill in fiscal year (FY) 1999, completed schizophrenia visits in each of the next 4 years (FY2000, FY2001, FY2002, FY2003), and had valid medication possession ratios (MPRs) in each of these years. We examined whether patients had consistently good adherence (MPRs >or= 0.8 in all 4 years), consistently poor adherence (MPRs < 0.8 in all years), or inconsistent adherence. We examined predictors of consistently poor or inconsistent adherence.
The cross-sectional prevalence of poor adherence among the patient population remained stable over time; 36%-37% were poorly adherent in each year. However, 61% of patients had adherence difficulties at some point over the 4-year period. Approximately 18% had consistently poor adherence, 43% were inconsistently adherent, and 39% had consistently good adherence. Patients who were younger and nonwhite, with a substance use diagnosis, a psychiatric hospitalization, or predominant treatment with first-generation antipsychotics, were more likely to have consistently poor adherence.
Antipsychotic adherence is not a stable trait; most patients have difficulties with adherence over time. Health organizations and clinicians must emphasize adherence-enhancing interventions that can be provided on a longer term basis to the majority of patients.
在任何给定时间,约40%的精神分裂症患者对抗精神病药物的依从性较差。然而,尽管患者的长期依从性对医疗服务有重要影响,但目前对此了解甚少。我们在一大群患者中,从总体和个体层面考察了4年期间抗精神病药物的依从性情况。
我们确定了34128名退伍军人事务部的患者,这些患者在1999财政年度被诊断为精神分裂症并开具了抗精神病药物处方,在接下来的4年(2000财政年度、2001财政年度、2002财政年度、2003财政年度)中每年都完成了精神分裂症诊疗,且在这些年份中每年都有有效的药物持有率(MPR)。我们考察了患者是否始终保持良好依从性(4年中MPR均≥0.8)、始终依从性差(所有年份MPR均<0.8)或依从性不一致。我们还考察了始终依从性差或不一致的预测因素。
患者群体中依从性差的横断面患病率随时间保持稳定;每年有36%-37%的患者依从性差。然而,61%的患者在4年期间的某个时间点存在依从性困难。约18%的患者始终依从性差,43%的患者依从性不一致,39%的患者始终保持良好依从性。年龄较小、非白人、有物质使用诊断、有精神科住院史或主要使用第一代抗精神病药物治疗的患者,更有可能始终依从性差。
抗精神病药物的依从性不是一个稳定的特征;大多数患者随着时间推移会出现依从性困难。卫生组织和临床医生必须强调可长期为大多数患者提供的增强依从性的干预措施。